Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pramlintide acetate Clear all
Completed Phase 2 Interventional

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

NCT00044707
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Not listed Phase 3 Interventional

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

NCT01137695
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
Cheryl Rosenfeld, DO
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Denville, New Jersey • Staten Island, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Sep 30, 2026, 1:10 AM EDT
Withdrawn Early Phase 1 Interventional

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT04252612
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Pramlintide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00112021
View directory record Official record
Conditions
Obesity
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
21
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT00107107
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

NCT00108004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Anaheim, California • Escondido, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Terminated Not applicable Interventional

Pramlintide Combined With Model Predictive Control Algorithm

NCT01434862
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Closed Loop System With Pramlintide Versus Exenatide

NCT01269008
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic ePID 2.0
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

NCT01708044
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide acetate, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Results available

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

NCT01841359
View directory record Official record
Conditions
Hypoglycemia, Evidence of Previous Gastric Surgery
Interventions
Pramlintide
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

NCT00206297
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 30, 2026, 1:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

NCT00673387
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, metreleptin, placebo-P, placebo-M
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

NCT00819234
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Pramlintide and Metreleptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 30, 2026, 1:10 AM EDT
Terminated Not applicable Interventional Results available

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-PORT, standard injections
Device · Other
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Sep 30, 2026, 1:10 AM EDT